A VISIONaerie® approach
We discover, develop and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases
News HighlightsAerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 mic... Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluati... Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financi...
Apr 22, 4:00 PM ET
52 - WEEK LOW/HIGH